MHT vs HRT: What’s the Difference (and Why It Matters for Your Treatment)

If you have spent any time reading about hormone therapy recently — in medical journals, on clinic websites, or in patient education materials — you have probably encountered two different terms used to describe what looks like the same treatment. Some sources call it HRT, hormone replacement therapy. Others call it MHT, menopausal hormone therapy. Some use them interchangeably. Some pick one and never explain why.

This article explains the difference between MHT and HRT, why the terminology shifted, what it tells you about how the medical field thinks about hormone therapy today, and what this means for women trying to make informed decisions about their care. The vocabulary matters more than it appears, because it reflects a meaningful evolution in clinical thinking — one that affects how therapy is prescribed, monitored, and discussed.

The short answer

MHT (menopausal hormone therapy) and HRT (hormone replacement therapy) refer to the same general category of treatment: the use of estrogen, progesterone, and sometimes testosterone to address the symptoms and health effects of menopause. In casual use and in most patient conversations, the terms are interchangeable.

The terminology shift from HRT to MHT, which began in clinical literature around 2017 and accelerated through the early 2020s, was deliberate. It reflects a change in how the medical field conceptualizes the goal of therapy. The old framing — replacement therapy — implied restoring hormones to premenopausal levels, as if menopause were a deficiency state to be corrected. The new framing — menopausal hormone therapy — acknowledges that menopause is a natural life stage, and that the goal of treatment is to address symptoms and reduce specific health risks rather than to reverse a deficiency.

It is, in short, a more precise term for what the therapy is actually doing.

Why the shift happened

The change in terminology did not happen in a vacuum. Several intersecting developments in the field led to the gradual abandonment of “replacement therapy” framing in favor of more clinically accurate language.

The reconceptualization of menopause itself. Earlier medical thinking treated menopause as something close to a disease — a deficiency state in which the body had stopped doing something it should be doing, and which therefore needed to be corrected through replacement. Modern thinking treats menopause as a normal life stage in which hormone levels naturally decline, producing symptoms in some women, increasing certain health risks in many, but not requiring “correction” in the sense the older framing implied.

The reality of dosing. Hormone therapy as practiced today does not aim to restore estrogen, progesterone, or testosterone to premenopausal levels. Doses are calibrated to manage symptoms and reduce specific risks (bone loss, cardiovascular disease, urogenital symptoms) while keeping hormone levels well below what a 30-year-old would have. The “replacement” language implied a target that the therapy was not actually pursuing.

The Women’s Health Initiative legacy. The WHI study results published in 2002 created a long shadow over hormone therapy. The initial reporting suggested HRT increased risks of breast cancer, cardiovascular disease, and other adverse outcomes — concerns that were later substantially refined but that drove a generation of women away from therapy and shaped a generation of clinical caution. Part of the move toward “MHT” language was a recognition that the older “HRT” framing carried associations with the pre-2002 era of higher-dose, less-individualized hormone replacement that the field has largely moved past.

International clinical practice. Most professional societies internationally — the International Menopause Society, the European Menopause and Andropause Society, and others — moved to “MHT” terminology earlier than United States practice. The shift in the U.S. has been partial and gradual, with many clinicians still using HRT, MHT, or both depending on context.

What this means for you as a patient

The terminology change is not a meaningful change in what therapy is available, what it does, or whether it is right for you. The medications are the same. The clinical evidence is the same. The decisions about whether to start therapy, what to use, and how to monitor are the same. If a clinic refers to “HRT” and a textbook refers to “MHT,” they are discussing the same thing.

But there are a few signals worth paying attention to:

A clinic that can explain both terms is operating at a higher clinical literacy level. Clinics that are aware of the terminology evolution — and can explain why it happened — are typically also aware of the broader evolution in hormone therapy practice: the move toward bioidenticals over older synthetic preparations, the move toward transdermal estrogen over oral, the more sophisticated thinking about timing of initiation, and the individualized approach that has replaced the one-size-fits-all protocols of earlier eras.

A clinic that uses outdated terminology exclusively may be operating with outdated tools. This is not a hard rule — many excellent clinicians use “HRT” simply because their patients use it and changing terminology mid-relationship creates confusion. But a clinic that uses “hormone replacement therapy” and seems to think the goal is restoring premenopausal hormone levels is operating with an outdated framework that may produce protocols that are too aggressive or that target the wrong outcomes.

The terminology is most useful as a window into how a clinic thinks. Ask the clinician how they describe what they do and why. The answer tells you more about their clinical approach than the specific words they choose.

The clinical evolution behind the terminology

The shift from HRT to MHT is one piece of a larger evolution in how hormone therapy is practiced. A few of the other changes that have happened over the same time period:

Lower doses. Modern protocols use significantly lower doses than the standard practice of the 1990s. Lower doses produce fewer side effects and a more favorable safety profile while still addressing the symptoms and health risks that justify therapy.

Bioidentical preference. The default has shifted toward bioidentical hormones — estradiol, progesterone, and testosterone in their molecularly identical forms — and away from older synthetic preparations like conjugated equine estrogens (CEE) and synthetic progestins like medroxyprogesterone acetate (MPA). Bioidentical hormones have a more favorable side effect profile and a metabolic pathway that more closely matches what the body does with its own hormones.

Delivery route precision. Modern practice increasingly favors transdermal estrogen (patches, gels) over oral estrogen because the transdermal route bypasses first-pass liver metabolism and has a more favorable cardiovascular and clotting risk profile. Oral progesterone, on the other hand, is often preferred for its sleep benefits and uterine protection effects.

Timing hypothesis. The clinical evidence increasingly supports the idea that hormone therapy initiated within roughly ten years of the final menstrual period (or before age 60) has a more favorable risk-benefit balance than therapy initiated significantly later. This nuance was not part of the older WHI-era thinking.

Individualized risk assessment. Modern practice involves more comprehensive evaluation of cardiovascular risk, breast cancer risk, clotting risk, and other factors that determine whether and how to prescribe therapy for a specific patient. The one-size-fits-all approach of earlier decades has been replaced by individualized clinical decision-making.

All of these changes happened over roughly the same period as the terminology shift, and all of them are part of why the field moved away from “HRT” as the standard term. The older language was associated with an older approach, and changing the words was part of signaling that the approach has changed.

Why patients still search “HRT”

Despite the clinical shift toward MHT terminology, the vast majority of patient searches still use “HRT.” There are several reasons.

Familiarity. Generations of women have heard the term HRT used to describe their mothers’ or grandmothers’ treatment. The vocabulary has been in cultural circulation for half a century.

Continuity in clinic communication. Most clinics in the United States still use “HRT” or “hormone replacement therapy” in their patient-facing materials, both because patients understand it and because the change to MHT has been gradual rather than universal.

Search engine inertia. Patients search what they know. The newer terminology has not been widely adopted in patient-facing language, so search behavior reflects the older term.

The practical implication is that a Houston patient searching for “HRT clinic Houston” or “best hormone replacement therapy in Houston” is searching for exactly the same thing as a patient searching for “MHT in Houston” — there is just a lot less search volume on the latter term. From the clinic’s perspective, this is why most Houston hormone therapy practices (including our HRT page) continue to use “hormone replacement therapy” as the primary descriptor while explaining the more current clinical thinking in the substance of how we practice.

When the distinction matters clinically

For most purposes, the HRT vs MHT distinction is semantic. There are a few contexts in which it actually matters:

When evaluating older medical literature. Research from before roughly 2010 was almost universally framed as “hormone replacement therapy” research, and many of those studies used the higher-dose, less-individualized protocols that the field has largely moved past. Modern MHT literature is studying different doses, different molecules, different delivery routes, and different patient populations. When comparing studies across decades, it is worth knowing whether the data is from the older or newer era of practice.

When discussing risks and benefits. Some of the older risk associations — particularly cardiovascular concerns and certain cancer concerns — were derived from studies that used older protocols. Modern MHT, with bioidentical hormones, transdermal delivery, and lower doses, has a different risk profile than the higher-dose oral CEE-plus-MPA combinations that defined the WHI era. A clinician who discusses HRT risks without acknowledging that the modern approach is different is working from outdated information.

When evaluating clinic approach. As noted above, a clinic that exclusively uses “hormone replacement therapy” language and seems to think the goal is restoring premenopausal levels is operating with an older framework. A clinic that can engage with the modern MHT framing — and explain what it actually means for protocol design — is typically operating with more current clinical thinking.

What good modern hormone therapy looks like

Regardless of which term is used, good modern hormone therapy involves several consistent elements:

Comprehensive baseline evaluation. A full hormone panel, metabolic markers, lipid panel, cardiovascular risk assessment, breast and pelvic exam where appropriate, and review of medical and family history. Not just FSH and a complaint of hot flashes.

Individualized protocol design. Decisions about which hormones to use, in what doses, through which delivery routes, are made based on the specific patient — her symptoms, her risk factors, her preferences, her goals — rather than on a clinic template.

Bioidentical preference where appropriate. Modern practice generally defaults to bioidentical hormones when they are available and clinically suitable, using synthetic preparations only when there is a specific clinical reason.

Transdermal estrogen preference. For estrogen specifically, transdermal delivery (patches, gels) is generally preferred over oral when there is no specific reason to use oral. The cardiovascular and clotting risk profile is more favorable.

Ongoing monitoring. Labs at 6-8 weeks after starting or after dose changes, quarterly during the first year, every six months once stable. Clinical follow-up on symptoms and quality of life at the same intervals.

Adjustment over time. The initial protocol is rarely the long-term protocol. Symptoms change, bodies change, and the therapy needs to evolve with the patient.

Periodic reassessment. Hormone therapy is not necessarily forever. Periodic discussion of whether to continue, taper, or stop is part of good care.

All of this can be called HRT, MHT, or simply “hormone therapy” — the labels matter less than the substance.

What to do with this knowledge

If you are considering hormone therapy and trying to evaluate Houston clinics, the terminology question is one useful filter. Ask the clinician how they describe what they do, and listen for whether they can explain the evolution in clinical thinking that has happened over the past two decades. Ask about doses, delivery routes, monitoring schedules, and bioidentical vs synthetic preferences. The answers will tell you more about the quality of care you can expect than any specific term.

Search for “HRT Houston” if that’s the language you know. The clinics worth working with will recognize that you are asking about modern hormone therapy and will provide it. They may or may not call it MHT in their own materials. What matters is the substance of the care, not the vocabulary.

If you are already on hormone therapy and your protocol was designed before roughly 2015, it is worth asking your current clinician whether the protocol still reflects current clinical thinking. Doses, molecules, and delivery routes have all evolved. Many patients are still on protocols that were appropriate when they were started but that are no longer the standard of care today.

About The Tide

The Tide is a peptide-focused medical clinic in Houston, Texas, located adjacent to the Texas Medical Center. We provide hormone therapy through our women’s hormone health and men’s hormone health services. Our approach reflects current clinical thinking on modern hormone therapy: bioidentical preferences where appropriate, transdermal estrogen delivery where indicated, individualized protocol design based on comprehensive labs and clinical evaluation, and ongoing monitoring with structured follow-up. We offer hormone replacement therapy, bioidentical hormones, hormone pellets, and testosterone replacement therapy based on what fits each patient. For deeper reading on how we approach hormone therapy, see our clinical standards.